The Significant Need for New Agents to Treat MDS

Josep M. Llovet, MD, PhD, discussed the updated data from the LEAP-012 trial in intermediate-stage hepatocellular carcinoma.

Zanubrutinib, obinutuzumab, and venetoclax delivered promising response and survival data for the treatment of patients with mantle cell lymphoma harboring a TP53 mutation.

Janelle Vicens, DNP, APRN, FNP-BC, and Sandra Sepulveda, AGPNP-BC, MSN, BMTCN, discussed what went into developing this Malignant Hematology and Bone Marrow Transplant APP Fellowship.

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed emerging endocrine therapies that are advancing breast cancer treatment.

John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.

During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.